Breaking News

Total CEO De Margerie Dies in Moscow Plane Crash, Interfax Says
Tweet TWEET

CEO of ARCA biopharma to Speak on Changing Paradigms in Drug Development at ACC.13 Conference on March 10, 2013

  CEO of ARCA biopharma to Speak on Changing Paradigms in Drug Development at
  ACC.13 Conference on March 10, 2013

Business Wire

BROOMFIELD, Colo. -- March 8, 2013

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing
genetically-targeted therapies for atrial fibrillation and other
cardiovascular diseases, announced today that Dr. Michael Bristow, President
and Chief Executive Officer, will present “The Changing Paradigms in Drug
Development” at conference session “Joint Symposium of the Heart Failure
Society and the American College of Cardiology II: Heart Failure Care in the
Era of Health Care Reform” at the American College of Cardiology 62^nd Annual
Scientific Sessions & Expo, being held March 9-11, 2013 in San Francisco,
California. The conference session is scheduled on Sunday, March 10, 2013,
from 12:30pm – 1:45pm Pacific.

More information about the conference is available at:
www.accscientificsession.org.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for
cardiovascular diseases. The Company's lead product candidate is Gencaro^TM
(bucindolol hydrochloride), an investigational, pharmacologically unique
beta-blocker and mild vasodilator being developed for the prevention of atrial
fibrillation. ARCA has identified common genetic variations that it believes
predict individual patient response to Gencaro, giving it the potential to be
the first genetically-targeted atrial fibrillation prevention treatment. For
more information please visit www.arcabiopharma.com.

Safe Harbor Statement

This press release and the associated presentation may contain
"forward-looking statements" for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements regarding genetic variations to predict
individual patient response to Gencaro, Gencaro’s potential to treat atrial
fibrillation, future treatment options for patients with atrial fibrillation
and the potential for Gencaro to be the first genetically-targeted atrial
fibrillation prevention treatment. Such statements are based on management's
current expectations and involve risks and uncertainties. Actual results and
performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including, without
limitation, the risks and uncertainties associated with: the Company's
financial resources and whether they will be sufficient to meet the Company's
business objectives and operational requirements; results of earlier clinical
trials may not be confirmed in future trials, the protection and market
exclusivity provided by the Company’s intellectual property; risks related to
the drug discovery and the regulatory approval process; and the impact of
competitive products and technological. These and other factors are identified
and described in more detail in ARCA’s filings with the SEC, including without
limitation the Company’s annual report on Form 10-K for the year ended
December 31, 2011 and subsequent filings. The Company disclaims any intent or
obligation to update these forward-looking statements.

Contact:

ARCA biopharma, Inc.
Derek Cole
Investor Relations Advisory Solutions
720.940.2163
 
Press spacebar to pause and continue. Press esc to stop.